Combined Bowel Urgency, Clinical Outcomes, and Quality of Life Improvement in Mirikizumab-Treated Ulcerative Colitis: A Step Toward Comprehensive Disease Management

Clicks: 1
ID: 317044
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #27 of 38 articles by views in Crohn s & Colitis 360

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background With increasing emphasis on patient-centric care, treatment goals for ulcerative colitis (UC) now include bowel urgency (BU), stool frequency, and rectal bleeding (RB) resolution, enhancement of overall well-being, and endoscopic remission (ER). This analysis evaluated the impact of adding BU improvement to clinical remission, defined by the modified Mayo score (RB, stool frequency, ER), on quality-of-life assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ). The effect of mirikizumab on achieving combined clinical, BU, and IBDQ remissions was also evaluated in the LUCENT-1 and -2 trials. Methods In LUCENT-1, patients were randomized 3:1 (mirikizumab to placebo) every 4 weeks. At week 12, mirikizumab responders were re-randomized 2:1 (mirikizumab to placebo) for 40 additional weeks in LUCENT-2. BU improvement was assessed using a clinically meaningful improvement (Urgency Numeric Rating Scale (UNRS) ≥ 3-point change) and BU remission (UNRS = 0 or 1). The impact of mirikizumab on achieving single and combined outcomes was determined at weeks 12 and 52. Results Significant IBDQ improvement at both timepoints (P ≤ .01) was observed by achieving both BU improvement and clinical remission versus clinical remission alone. Significantly more mirikizumab-treated patients achieved single and combined endpoints of clinical, BU, and IBDQ remissions versus placebo (P ≤ .05). Conclusions The addition of BU improvement in patients who had already attained clinical response or remission is associated with greater quality of life. Mirikizumab delivered comprehensive benefit for patients with UC by relieving BU symptoms, resolving endoscopic inflammation, and enhancing overall well-being concurrently.
Reference Key
openalex_W7164348237 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stefan Schreiber, Jianmin Wu, Yajie Duan, Anthony Keohane, Seyedehsan Navabi, David T Rubin
Journal Crohn s & Colitis 360
Year 2026
DOI
10.1093/crocol/otag051
URL
https://doi.org/10.1093/crocol/otag051
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.